Harwood Feffer LLP Announces Investigation of United Therapeutics Corporation
Jul 28, 2017
NEW YORK, July 28, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ:UTHR), concerning whether the board has breached its fiduciary duties to shareholders.
On July 27, 2017, the Company disclosed that it recorded a $210 million relating to a potential settlement in connection with an investigation by the Department of Justice regarding the Company's possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act resulting from the Company's contributions to certain charities. Our investigation concerns whether the Company's board of directors breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own United Therapeutics shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Daniella Quitt, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP